What is “The Magnifying LeNS?”

The Magnifying LeNS is our new quarterly highlights of the lung cancer treatment landscape. In this series, you will receive articles written by our Science & Research team intended to educate and empower patients on the latest trends in clinical trials, biomarker testing, GO2 Foundation-driven research, and FDA-approved treatment options. In addition, we expect future issues to recap practice-changing advances and highlights from major scientific conferences.
In today’s lung cancer care landscape, biomarker testing has become a crucial part of the treatment decision for many oncologists. Targeted therapies can be more effective than chemotherapy for patients with driver mutations including approved medications for patients with different driver mutations including ROS1, MET, NTRK, and RET.
Approximately 30% of Non-Small Cell Lung Cancers (NSCLC) have an EGFR mutation. For these patients EGFR targeted therapy has greatly increased survival. Tagrisso (osimertinib) has become the drug of choice for EGFR+ (positive) NSCLC treatment, however, Tagrisso resistance remains a problem with a significant group of EGFR+ patients.
Patients often hear the words clinical trial and don’t know what to expect or sometimes even what a clinical trial is. GO2 Foundation has put together a list of frequently asked questions surrounding clinical trials for you to have a better understanding of how clinical trials relate to your treatment journey.
Are scientists learning enough about how people just like you respond to new treatments? You may be surprised. Clinical trial participation rates among people with cancer in the United States are low, with only about 8% of those diagnosed joining a trial.

Rates of participation for some racial/ethnic groups are much lower than others.

The percentages for clinical trials participation are: 1

- 83% for Caucasians
- 6% for African Americans
- 3% for Asian Americans
- 2% for Hispanics


Learning About Everyone: The Importance of Advancing Inclusive Research
The Lung Cancer Registry (LCR), created by GO2 Foundation for Lung Cancer, is a global online database that was launched in 2016. The LCR was designed so that patients could contribute their individual experiences with lung cancer through survey questions asking about the patient, their medical history and diagnosis, treatment, outcomes, and quality of life. By joining our growing registry, represented by over 2,300 members in more than 40 countries and 6 continents across the world, you are giving researchers access to crucial data that will help make new discoveries.
2020 started off on a high note – we were celebrating the largest single year drop in cancer mortality. Then COVID-19 showed up and the cancer world was put on high alert. Patients with lung cancer are particularly at risk, with much higher mortality rates from the virus compared to the general public.
THANK YOU TO OUR SPONSORS

Lilly Oncology

Bristol Myers Squibb
About Us

Founded by patients and survivors, GO2 Foundation for Lung Cancer transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

DONATE TODAY!
Contact Us

Email: support@go2foundation.org | HelpLine: 1-800-298-2436 (9-5 EDT)

Washington, DC
Phone: 202-463-2080

San Francisco Bay Area
Phone: 650-598-2857